The Serum Albumin pipeline drugs market research report outlays comprehensive information on the Serum Albumin targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Serum Albumin pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Gastrointestinal which include the indications Oncology, Ovarian Cancer, Ascites, and Decompensated Cirrhosis. It also reviews key players involved in Serum Albumin targeted therapeutics development with respective active and dormant or discontinued products.
The Serum Albumin pipeline targets constitutes close to six molecules. Out of which, approximately six molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Preclinical, and Discovery stages are 1, 4, and 1 respectively.
Serum Albumin overview
Serum Albumin is the most abundant protein in the human body that is encoded by a gene ALB. It is present in the blood and is synthesized by the liver. This protein functions in the regulation of blood plasma colloid osmotic pressure and acts as a carrier protein for a wide range of endogenous molecules including hormones, fatty acids, and metabolites, as well as exogenous drugs. This transport function is crucial for maintaining homeostasis in the body. It is water-soluble and has a high degree of flexibility, allowing it to perform various functions in the bloodstream. Serum albumin has a relatively long half-life in the bloodstream, contributing to its stability and sustained functions. Low levels of serum albumin may be associated with conditions such as malnutrition, liver disease, or kidney disease.
For a complete picture of Serum Albumin’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
